Published • loading... • Updated
Kodiak Sciences Stock Surges 125% After Late-Stage Drug Trial Success
Summary by Forbes
20 Articles
20 Articles
The Billings Gazette+12 Reposted by 12 other sources
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
Kodiak Sciences to Host Webcast on Monday, September 28 at 8:30 AM Eastern Time
·Billings, United States
Read Full Article
Kodiak Sciences Shares More Than Double as Wet AMD Drug Zenkuda Meets Primary Goal in Phase 3 DAYBREAK Trial
Kodiak Sciences shares surged 143% after the biotech said Zenkuda and tabirafusp-ted met key Phase 3 goals in wet age-related macular degeneration, though full data and regulatory review remain pending.
·New York, United States
Read Full Article
The Kodiak Sciences shares close at $32.35 on September 25, down 2.62%. The technical structure remains fragile, with the price below all major moving averages. However, the positive data of the AMD trial with Zenkuda and the Overweight rating of Cantor Fitzgerald reopen prospects that traders observe carefully. KOD
Coverage Details
Total News Sources20
Leaning Left1Leaning Right1Center11Last UpdatedBias Distribution84% Center
Bias Distribution
- 84% of the sources are Center
84% Center
C 84%
Factuality
To view factuality data please Upgrade to Premium
